Novo Nordisk to Seek China Approval for Oral Wegovy Weight-Loss Pill
NVO•Novo Nordisk plans to seek regulatory approval in China very soon for its oral Wegovy weight-loss drug, aiming to penetrate the world’s second-largest pharma market. The oral formulation is designed to boost patient uptake by offering a pill alternative to the injectable version.
1. Planned China Filing for Oral Wegovy
Novo Nordisk said it will soon seek regulatory approval in China for its oral version of Wegovy, marking its entry into the country’s expanding obesity treatment market. The oral formulation aims to enhance patient accessibility and accelerate market penetration by offering a noninvasive alternative to injections.
